MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

E. Jimenez Alguilar; J. Gainor; S. Kravets; S. Khosrowjerdi; C. Lydon; A. Adeni; S. Subegdjo; H. Rizvi; M. Hellmann; M. Awad

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

【24h】

MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

机译：NSCLC患者的MA04.05患者用第一线彭洛洛洛瑞拉姆（Pembrolizumab）和50-74％的PD-L1 TPS 75-100％或50-89％Vs 90-100％

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共2页
作者
E. Jimenez Alguilar; J. Gainor; S. Kravets; S. Khosrowjerdi; C. Lydon; A. Adeni; S. Subegdjo; H. Rizvi; M. Hellmann; M. Awad;
展开▼
作者单位

University Hospital 12 de Octubre;

Massachusetts General Hospital;

Biostatistics and Computational Biology Dana-Farber Cancer Institute;

Massachusetts General Hospital;

Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;

Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;

Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;

Memorial Sloan Kettering Cancer Center;

Memorial Sloan Kettering Cancer Center;

Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100% [J] . E. Jimenez Alguilar, J. Gainor, S. Kravets, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：NSCLC患者的MA04.05患者用第一线彭洛洛洛瑞拉姆（Pembrolizumab）和50-74％的PD-L1 TPS 75-100％或50-89％Vs 90-100％
2. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of >= 50% [J] . Cortellini Alessio, Tiseo Marcello, Banna Giuseppe L., Cancer immunology, immunotherapy : . 2020,第11期

机译：先进的NSCLC患者的临床病理学与先进的NSCLC患者的效果和PD-L1表达> = 50％
3. Tumor metabolic volume by 18 F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1?≥?50% [J] . Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Scientific reports. . 2020,第1期

机译：肿瘤代谢体积18 F-FDG-PET作为PD-L1的NSCLC患者的第一线PEMBROLIZUAB的预测预测因子？≥？50％
4. Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy [C] . B. Farina, A. D. Ramos Guerra, C. Palacios Miras, IEEE International Symposium on Biomedical Imaging . 2021

机译：用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1 Metastatic NSCLC [O] . Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, 2020

机译：PEMBROLIZUAB +化疗与Nivolumab + IPILIMILAB的匹配间接比较作为PD-L1TPS≥1％转移NSCLC患者的一线疗法
7. MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1 [O] . Y. Wu, L. Zhang, Y. Fan, 2019

机译：Ma11.02 Keynote-042中国研究：一线Pembrolizumab在中国高级NSCLC患者中的化疗，PD-L1TPS≥1％

MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

著录项

引文网络

相似文献

相关主题

期刊订阅